Cannabis Bioscience delays quarterly report as annual audit remains incomplete
CBIH•Cannabis Bioscience International Holdings delayed its quarterly report for the period ended August 31, 2026, because its annual audit remains unfinished, and said filing within the five-day extension period is not assured. It expects revenue of about $1,000, down from $24,200, and a net loss of about $172,000, up from $82,645 a year earlier.
1. Filing delay
Cannabis Bioscience International Holdings delayed its Form 10-Q for the quarter ended August 31, 2026, because it could not complete the financial information. Its audit for the fiscal year ended May 31, 2026, remains unfinished, preventing completion of the quarterly statements; the annual report also remains unfiled. The company said it is not assured it will file within the five-day extension period.
2. Expected results
Quarterly revenue is expected to be approximately $1,000, compared with $24,200 a year earlier, reflecting termination of the clinical-trial business on July 31, 2026. The company projects a net loss of approximately $172,000, versus $82,645 a year earlier, citing higher compensation costs, increased interest expense and the absence of derivative-related gains.
